Amyloid Precursor Protein (APP) - Pipeline Review, H2 2016

  • ID: 3845363
  • Report
  • 46 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • CereSpir Incorporated
  • QR Pharma, Inc.
  • MORE
Amyloid Precursor Protein (APP) - Pipeline Review, H2 2016

Summary

‘Amyloid Precursor Protein (APP) - Pipeline Review, H2 2016’, provides in depth analysis on Amyloid Precursor Protein (APP) targeted pipeline therapeutics.

The report provides comprehensive information on the Amyloid Precursor Protein (APP), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Amyloid Precursor Protein (APP) targeted therapeutics development and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Amyloid Precursor Protein (APP)
- The report reviews Amyloid Precursor Protein (APP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Amyloid Precursor Protein (APP) targeted therapeutics and enlists all their major and minor projects
- The report assesses Amyloid Precursor Protein (APP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Amyloid Precursor Protein (APP) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Amyloid Precursor Protein (APP)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Amyloid Precursor Protein (APP) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • CereSpir Incorporated
  • QR Pharma, Inc.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Amyloid Precursor Protein (APP) Overview

Therapeutics Development

Amyloid Precursor Protein (APP) - Products under Development by Stage of Development

Amyloid Precursor Protein (APP) - Products under Development by Therapy Area

Amyloid Precursor Protein (APP) - Products under Development by Indication

Amyloid Precursor Protein (APP) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Amyloid Precursor Protein (APP) - Products under Development by Companies

Amyloid Precursor Protein (APP) - Products under Development by Universities/Institutes

Amyloid Precursor Protein (APP) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Amyloid Precursor Protein (APP) - Companies Involved in Therapeutics Development

CereSpir Incorporated

QR Pharma, Inc.

Amyloid Precursor Protein (APP) - Drug Profiles

Antisense RNAi Oligonucleotides to Inhibit Amyloid Precursor Protein for Amyloidosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARN-2955 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARN-2966 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Bisnorcymserine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSP-1103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Posiphen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Amyloid Beta Protein for Alzheimer's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tropisetron hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Amyloid Precursor Protein (APP) - Dormant Projects

Amyloid Precursor Protein (APP) - Featured News & Press Releases

Jul 14, 2015: CereSpir Obtains New Patent From USPTO Covering the Optimal Synthetic Route for Commercial Manufacture of CSP-1103 in Late Stage Development to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease

Jul 01, 2015: CereSpir Submits Special Protocol Assessment Request to FDA for a Phase 3 Clinical Trial to Test the Ability of CSP-1103 to Slow the Progression of Mild Cognitive Impairment Due to Alzheimer's Disease

Nov 10, 2014: Buck Institute's First Clinical Trial Underway in Australia

Jun 09, 2014: Aria Announces Promising Results with Alzheimers Compound

Oct 10, 2013: QR Pharma and UCLA Awarded $3 Million USARMY Grant to Test Posiphen in Rat Models of Concussion and Blunt Head Trauma

Jul 26, 2013: CERESPIR INCORPORATED IS PLEASED WITH POSITIVE INTERIM PHASE 2 RESULTS FOR CHF 5074 IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT, PRESENTED BY CHIESI AT THE AAIC 2013 MEETING IN BOSTON

Oct 22, 2012: QR Pharma's Posiphen Restores Brain Function, Cognition And Memory In Transgenic Alzheimer Mice

Jul 24, 2012: QR Pharma Starts Phase I Clinical Study For Bisnorcymserine

Jul 17, 2012: QR Pharma Announces Publication On Posiphen Clinical Trials Showing Promise For Alzheimer's Patients

Jul 10, 2012: QR Pharma To Present Clinical Data On Posiphen At Alzheimer's Association International Conference

Mar 06, 2012: QR Pharma Receives $468,000 From Michael J. Fox Foundation To Test Posiphen For Treatment Of Parkinson's Disease

Oct 13, 2011: QR Pharma Reports Results From SBIR Grant By NIA/NIH To Study Posiphen And Metabolites In Various Models

Jul 12, 2011: QR Pharma To Present Poster At International Conference On Alzheimer's Disease

Jun 02, 2011: QR Pharma To Present At Annual World Pharma Congress On Parkinson's Disease

Jan 19, 2011: QR Pharma To Present Poster At 44th Winter Conference On Brain Research

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Number of Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016

Number of Products under Investigation by Universities/Institutes, H2 2016

Products under Investigation by Universities/Institutes, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Pipeline by CereSpir Incorporated, H2 2016

Pipeline by QR Pharma, Inc., H2 2016

Dormant Projects, H2 2016 35List of Figures

Number of Products under Development for, H2 2016

Number of Products under Development by Therapy Area, H2 2016

Number of Products under Development by Indication, H2 2016

Comparative Analysis by Early Stage Products, H2 2016

Assessment by Monotherapy/Combination Products, H2 2016

Number of Products by Stage and Mechanism of Actions, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Type, H2 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • CereSpir Incorporated
  • QR Pharma, Inc.
  • MORE
Amyloid Precursor Protein (APP) Amyloid precursor protein (APP) is an integral membrane protein expressed in synapses of neurons. It functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. It is involved in cell mobility and transcription regulation through protein-protein interactions. It regulates neurite outgrowth through binding to components of the extracellular matrix such as heparin and collagen I and IV.

Amyloid Precursor Protein (APP) pipeline Target constitutes close to 8 molecules. Out of which approximately 5 molecules are developed by Companies and remaining by the Universities/Institutes. The molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 1 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 2 molecules, respectively.

Our latest report Amyloid Precursor Protein (APP) – Pipeline Review, H2 2016, outlays comprehensive information on the Amyloid Precursor Protein (APP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Amyloid Precursor Protein (APP) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Product cover images may vary from those shown
5 of 6
CereSpir Incorporated
QR Pharma, Inc.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll